Post by deborah on Jun 23, 2019 16:25:26 GMT
Fascinating research!
translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-1840-4#Sec2
Conclusion
From 1960 to the present, many steps forward have been made in identifying how vitamin D metabolites and the GH/IGF-1 axis interact. Although limited by some bias, most of the studies confirm the existence of this close link. From the set of collected works in this review, it is possible to derive some significant data, such as the higher probability of hypovitaminosis D in GHD subjects, and hypovitaminosis persistence in this population despite the substitution treatment with GH; data on vitamin D supplementation efficacy in the general population on IGF-1 levels are conflicting.
Based on these results, it is therefore possible to define some important measures. For example, a screening for the determination of vitamin D deficiency is currently recommended only for individuals who present risk factors for hypovitaminosis [26], but a short stature is not included among them. Considering the results of the clinical studies reported in this review, we suggest investigating children subjects with GHD for vitamin D deficiency both at diagnosis and during follow-up and in presence of deficiency considering vitamin D supplementation. An interesting topic to be addressed in future scientific work could consider the effects of the coadministration of vitamin D and rGH on the auxologic parameters of the patients affected by GHD and if the vitamin D supplementation could reduce the rGH dosage. More research is needed to understand the vitamin D-GH biological interaction in other diseases characterized by short stature.
Other information obtained is the relationship between IGF-1 and vitamin D metabolites. Although this relationship seems to be significant only after supplementary vitamin D therapy, it is possible to hypothesize that in subjects with hypovitaminosis D, this should be corrected before making inquiries into the presence of IGF-1 values below the norm to optimize the diagnosis of GHD, which is still complex and nonstandardized. Since both vitamin D metabolites and the GH/IGF-1 axis act in a complex way and undergo numerous interferences from other factors (environmental, hormonal, nutritional, etc.) it would be important to consider them in future studies to limit bias.
In conclusion, further research is needed to fully understand how vitamin D and growth are intertwined. Specifically, many more homogeneous studies are required with larger populations and fewer confounding factor
translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-1840-4#Sec2
Conclusion
From 1960 to the present, many steps forward have been made in identifying how vitamin D metabolites and the GH/IGF-1 axis interact. Although limited by some bias, most of the studies confirm the existence of this close link. From the set of collected works in this review, it is possible to derive some significant data, such as the higher probability of hypovitaminosis D in GHD subjects, and hypovitaminosis persistence in this population despite the substitution treatment with GH; data on vitamin D supplementation efficacy in the general population on IGF-1 levels are conflicting.
Based on these results, it is therefore possible to define some important measures. For example, a screening for the determination of vitamin D deficiency is currently recommended only for individuals who present risk factors for hypovitaminosis [26], but a short stature is not included among them. Considering the results of the clinical studies reported in this review, we suggest investigating children subjects with GHD for vitamin D deficiency both at diagnosis and during follow-up and in presence of deficiency considering vitamin D supplementation. An interesting topic to be addressed in future scientific work could consider the effects of the coadministration of vitamin D and rGH on the auxologic parameters of the patients affected by GHD and if the vitamin D supplementation could reduce the rGH dosage. More research is needed to understand the vitamin D-GH biological interaction in other diseases characterized by short stature.
Other information obtained is the relationship between IGF-1 and vitamin D metabolites. Although this relationship seems to be significant only after supplementary vitamin D therapy, it is possible to hypothesize that in subjects with hypovitaminosis D, this should be corrected before making inquiries into the presence of IGF-1 values below the norm to optimize the diagnosis of GHD, which is still complex and nonstandardized. Since both vitamin D metabolites and the GH/IGF-1 axis act in a complex way and undergo numerous interferences from other factors (environmental, hormonal, nutritional, etc.) it would be important to consider them in future studies to limit bias.
In conclusion, further research is needed to fully understand how vitamin D and growth are intertwined. Specifically, many more homogeneous studies are required with larger populations and fewer confounding factor